Your browser doesn't support javascript.
loading
Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
Tsang, Erica S; Topham, James T; Karasinska, Joanna M; Lee, Michael K C; Williamson, Laura M; Mendis, Shehara; Denroche, Robert E; Jang, Gun Ho; Kalloger, Steve E; Moore, Richard A; Mungall, Andrew J; Bathe, Oliver F; Tang, Patricia A; Notta, Faiyaz; Wilson, Julie M; Laskin, Janessa; O'Kane, Grainne M; Knox, Jennifer J; Goodwin, Rachel A; Loree, Jonathan M; Jones, Steven J M; Marra, Marco A; Gallinger, Steven; Schaeffer, David F; Renouf, Daniel J.
Afiliación
  • Tsang ES; BC Cancer, Vancouver, British Columbia, Canada.
  • Topham JT; Pancreas Centre BC, Vancouver, British Columba, Canada.
  • Karasinska JM; Pancreas Centre BC, Vancouver, British Columba, Canada.
  • Lee MKC; Pancreas Centre BC, Vancouver, British Columba, Canada.
  • Williamson LM; BC Cancer, Vancouver, British Columbia, Canada.
  • Mendis S; Pancreas Centre BC, Vancouver, British Columba, Canada.
  • Denroche RE; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
  • Jang GH; BC Cancer, Vancouver, British Columbia, Canada.
  • Kalloger SE; Pancreas Centre BC, Vancouver, British Columba, Canada.
  • Moore RA; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Mungall AJ; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Bathe OF; Pancreas Centre BC, Vancouver, British Columba, Canada.
  • Tang PA; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
  • Notta F; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
  • Wilson JM; University of Calgary, Calgary, Alberta, Canada.
  • Laskin J; University of Calgary, Calgary, Alberta, Canada.
  • O'Kane GM; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Knox JJ; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Goodwin RA; BC Cancer, Vancouver, British Columbia, Canada.
  • Loree JM; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Jones SJM; Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
  • Marra MA; The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Gallinger S; BC Cancer, Vancouver, British Columbia, Canada.
  • Schaeffer DF; Pancreas Centre BC, Vancouver, British Columba, Canada.
  • Renouf DJ; Canada's Michael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Clin Cancer Res ; 27(1): 246-254, 2021 01 01.
Article en En | MEDLINE | ID: mdl-32958704
ABSTRACT

PURPOSE:

With the rising incidence of early-onset pancreatic cancer (EOPC), molecular characteristics that distinguish early-onset pancreatic ductal adenocarcinoma (PDAC) tumors from those arising at a later age are not well understood. EXPERIMENTAL

DESIGN:

We performed bioinformatic analysis of genomic and transcriptomic data generated from 269 advanced (metastatic or locally advanced) and 277 resectable PDAC tumor samples. Patient samples were stratified into EOPC (age of onset ≤55 years; n = 117), intermediate (age of onset 55-70 years; n = 264), and average (age of onset ≥70 years; n = 165) groups. Frequency of somatic mutations affecting genes commonly implicated in PDAC, as well as gene expression patterns, were compared between EOPC and all other groups.

RESULTS:

EOPC tumors showed significantly lower frequency of somatic single-nucleotide variant (SNV)/insertions/deletions (indel) in CDKN2A (P = 0.0017), and were more likely to achieve biallelic mutation of CDKN2A through homozygous copy loss as opposed to heterozygous copy loss coupled with a loss-of-function SNV/indel mutation, the latter of which was more common for tumors with later ages of onset (P = 1.5e-4). Transcription factor forkhead box protein C2 (FOXC2) was significantly upregulated in EOPC tumors (P = 0.032). Genes significantly correlated with FOXC2 in PDAC samples were enriched for gene sets related to epithelial-to-mesenchymal transition (EMT) and included VIM (P = 1.8e-8), CDH11 (P = 6.5e-5), and CDH2 (P = 2.4e-2).

CONCLUSIONS:

Our comprehensive analysis of sequencing data generated from a large cohort of PDAC patient samples highlights a distinctive pattern of biallelic CDKN2A mutation in EOPC tumors. Increased expression of FOXC2 in EOPC, with the correlation between FOXC2 and EMT pathways, represents novel molecular characteristics of EOPC.See related commentary by Lou, p. 8.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Carcinoma Ductal Pancreático Límite: Aged / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Adenocarcinoma / Carcinoma Ductal Pancreático Límite: Aged / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Canadá